Elevidys (delandistrogene moxeparvovec-rokl) – New orphan drug approval
June 22, 2023, the FDA announced the approval of Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl), for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.
Top